Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Vincent Meininger Angela Genge 1 Leonard van den Berg 2 Wim Robberecht 3 Albert Ludolph 4 Adriano Chiò 5 Seung Kim P Nigel Leigh 6 Matt Kiernan 7 Jeremy Shefner 8 Claude Desnuelle 9 Karen Morrison 10, 11 Susanne Petri 12 Diane Boswell 13 Jane Temple 13 Rajat Mohindra 13 Matt Davies 13 Jonathan Bullman 13 Paul Rees 13 Arseniy Lavrov 13 William Camu 14 Jerzy Daniluk Anne Dekker Alain Destée Matthew Devine Stephen Dewall Johannes Dorst Giuseppe Fuda Harutoshi Fujimura Andreas Funke Torsten Grehl Julian Grosskreutz Usha Gungabissoon Rob Henderson Peggy Ho William Huynh Saiju Jacob Raul Juntas-Morales 14 Byung-Jo Kim Xenia Kobeleva Sonja Koerner Stephen Kolb Katja Kollewe Lawrence Korngut Géraldine Lautrette 15 Amy Lee Anthony Lynch Rami Massie Genevieve Matte Darryl Menezes Stefano Milleri Linda Nichols Kazutoshi Nishiyama Mieko Ogino Chris Parkinson Pierre-François Pradat Tino Prell Jeffrey Price Eleanor Ramsey Thomas Ringer Kristiana Salmon Christen Shoesmith Marie Helene Soriani Marloes Stam Erik Steinberg Rob Stubbs Herman Sullivan Philip van Damme 3 Michael van Es Anne Visser Mary Lou Watson Andrea Sylvia Winkler Lorne Zinman Margie Zoing
Abstract : Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1G93A mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a first-in-human trial. Therefore, we aimed to assess the safety and efficacy of ozanezumab in patients with ALS.
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-01785450
Contributeur : Mélanie Karli <>
Soumis le : vendredi 4 mai 2018 - 13:49:27
Dernière modification le : mardi 26 mai 2020 - 18:50:59

Lien texte intégral

Identifiants

Collections

Citation

Vincent Meininger, Angela Genge, Leonard van den Berg, Wim Robberecht, Albert Ludolph, et al.. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, Elsevier, 2017, 16 (3), pp.208 - 216. ⟨10.1016/S1474-4422(16)30399-4⟩. ⟨hal-01785450⟩

Partager

Métriques

Consultations de la notice

262